Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Starpharma Pty Ltd. is currently managing 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. This distribution of active matters suggests a multi-faceted approach to their intellectual property, where different technical aspects are being pursued simultaneously. Having 2 pending office actions allows the company to build a broader patent footprint within the Biotechnology & Pharmaceuticals field.
The portfolio involves 2 distinct examiners and 2 distinct art units, which introduces variety into the prosecution process. Because the work is split between 2 distinct examiners, the company must manage multiple sets of examiner preferences and procedural styles. The involvement of 2 distinct art units suggests that the company's biotechnology technologies may span different functional categories within the USPTO's classification system.
The busiest examiner, MEJIAS, SAMANTHA LEE, is responsible for 1 busiest examiner pending action. While MEJIAS, SAMANTHA LEE handles 1 busiest examiner pending action, the other pending matter is overseen by a different examiner, requiring a flexible prosecution strategy. Practitioners should ensure that the arguments used across the 2 pending office actions are harmonized to maintain the overall integrity of the Biotechnology & Pharmaceuticals portfolio.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MEJIAS, SAMANTHA LEE | 1 | 46.4% | +40.9% |
| HOERNER, PAUL ELLSWORTH | 1 | 50.0% | +62.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17919155 | METHOD OF PROPHYLAXIS OF CORONAVIRUS AND/OR RESPIRATORY SYNCYTIAL VIRUS INFECTION | HOERNER, PAUL ELLSWORTH | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17928306 | THERAPEUTIC CONJUGATES | MEJIAS, SAMANTHA LEE | — |
| 17919155 | METHOD OF PROPHYLAXIS OF CORONAVIRUS AND/OR RESPIRATORY SYNCYTIAL VIRUS INFECTION | HOERNER, PAUL ELLSWORTH | — |
| Art Unit | Apps |
|---|---|
| 1618 | 1 |
| 1611 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17928306 | THERAPEUTIC CONJUGATES | MEJIAS, SAMANTHA LEE | 1618 | §103Other | Final Rejection | — | Pending | Nov 29, 2022 |
| 17919155 | METHOD OF PROPHYLAXIS OF CORONAVIRUS AND/OR RESPIRATORY SYNCYTIAL VIRUS INFECTION | HOERNER, PAUL ELLSWORTH | 1611 | §103§112 | Final Rejection | — | Pending | Oct 14, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial